Artgen invests in biotech startup Aden

Artgen Group has provided a convertible loan of ₽20 million to biotech startup Adena. Funds will be used to develop a portfolio of drugs based on adeno-associated viruses for the prevention and therapy of HPV-associated cancers. Drugs for the prevention and treatment of cat allergic disease. As well as drugs against respiratory syncytial virus and a therapeutic drug based on VEGF for the therapy of age-related diseases.